The Salk Polio Vaccine Trial of 1954: Risks, randomization and public involvement in research

Clinical Trials

Volumn 1, Issue 1, 2004, Pages 122-130

  Dawson, Liza ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLIOMYELITIS VACCINE;

ARTICLE; CHILD; CLINICAL TRIAL; CONSUMER; CONTROLLED CLINICAL TRIAL; HISTORY; HUMAN; POLIOMYELITIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; UNITED STATES;

CHILD; CONSUMER PARTICIPATION; HISTORY, 20TH CENTURY; HUMANS; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; UNITED STATES;

EID: 33644682288     PISSN: 17407745     EISSN: None     Source Type: Journal    
DOI: 10.1191/1740774504cn010xx     Document Type: Article

References (28)

1. McMichael A.J., Hanke T. HIV vaccines 1983-2003. Nat Med 2003; 9: 874–80.
2. Benison S. Tom Rivers: reflections on a life in medicine and science. Boston: MIT Press, 1967.
3. De Kruif P. Activities of the NFIP in the field of virus research. New York: National Foundation for Infantile Paralysis, Inc., 1939.
4. Carter R. Breakthrough: the saga of Jonas Salk. New York: Trident Press, 1966.
5. New York Times, Nov 21, 1951. $4,000,000 sought in polio drive here.
6. New York Times, June 3, 1952. Record polio donations.
7. National Foundation for Infantile Paralysis. Annual Reports 1951–1955.
8. Deignan L.D., Miller E. The support of research in medical and allied fields for the period 1946 through 1951. Science 1952; 115: 321–43.
9. Berk L.B. Polio vaccine trials of 1935. Trans Coll Phys Philadelphia 1989; 11: 321–36.
10. Paul J. History of poliomyelitis. New Haven: Yale University Press, 1971.
11. Enders J.F., Weller T.H., Robbins F.C. Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science 1949; 109: 85–87.
12. Morgan I.M. Level of serum antibody associated with intracerebral immunity in monkeys vaccinated with Lansing poliomyelitis virus. J Immunol 1949; 62: 301–10.
13. Salk J.E. Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines. Am J Public Health 44: 563–70.
14. Smith J.S. Patenting the sun. New York: William Morrow, 1990.
15. Meier P. Safety testing of poliomyelitis vaccine. Science 1957; 125: 1067–1071.
16. Salk J.E. Studies in human subjects on active immunization against poliomyelitis. JAMA 1953; 151: 1081–1098.
17. Meldrum M.L. “Departures from the design”: the randomized clinical trial in historical context, 1946–1970. PhD Thesis, State University of New York at Stonybrook, 1994.
18. Francis T. Evaluation of the 1954 Field Trial of Poliomyelitis Vaccine: Final Report. Ann Arbor: Edward Brothers, Inc, 1957.
19. New York Times, April 5, 1955. Health units call polio vaccine safe.
20. Vaccine Evaluation Center, University of Michigan. Evaluation of 1954 Field Trial of Poliomyelitis Vaccine. Summary Report. April 12, 1955. Ann Arbor, Michigan.
21. Advisory Committee on Human Radiation Experiments. Final Report. Washington, DC: US Government Printing Office, 1995: 113–114.
22. Brownlee K.A. Statistics of the 1954 polio vaccine trials. J Am Stat Assoc 1955; 50: 1005–1013.
23. US Public Health Service. Technical Report on Salk Poliomyelitis Vaccine and Report on vaccine Produced by the Cutter Laboratories. US Department of Health, Education and Welfare, 1955.
24. Kapikian A.Z. A rotavirus vaccine for prevention of severe diarrhoea of infants and young children: development, utilization and withdrawal. Novartis Symposium 238: Gastroentereisis Viruses. John Wiley and Sons, 2001.
25. Pollak M. Doctors” ghting backlash over vaccines. New York Times, April 27, 1999.
26. Williams, L. The most worrisome risks deserve the least attention. Baltimore Sun, September 28, 2003.
27. Jansen V.A., Stollenwerk N., Jensen H.J., Ramsay M.E., Edmunds W.J., Rhodes C.J. Measles outbreaks in a population with declining vaccine uptake. Science 2003; 301: 804.
28. Scott E.C. The National Childhood Vaccine Injury Act turn” fteen. Food Drug Law J 2001; 56: 351–365.